Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma

Recruiting

Phase 2

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Sponsor:

Mural Oncology, Inc

Code:

NCT04830124

Conditions

Cutaneous Melanoma

Mucosal Melanoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Nemvaleukin Alfa Subcutaneous

Nemvaleukin Alfa Intravenous

Nemvaleukin Alfa Intravenous Less Frequent Dosing

Pembrolizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-16. This information was provided to ClinicalTrials.gov by Mural Oncology, Inc on 2024-07-01.